Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2017—Meridian has developed anti-müllerian hormone antibodies produced in chickens using a synthetic peptide representing a linear epitope on the human AMH protein. Initial purification of total IgY from eggs was followed by affinity purification against the peptide as an immunogen to yield a monospecific antibody. All antibodies can be used in ELISA.
May 2017—Sarstedt expanded its line of Multiply-µStrip PCR tubes to include a white option for qPCR. The reflective white wells maximize fluorescent signal intensity, minimize cross-talk, and enable volume reduction of expensive reagents without compromising sensitivity or stability.
May 2017—Streck and GenomePrecision Technology, an integrated molecular diagnostics distributor in China, have signed a distribution agreement for Streck’s cell stabilization, molecular, urinalysis, and flow cytometry products.
May 2017—Accelerate Diagnostics announced that the FDA has granted the de novo request to market the Accelerate Pheno system and Accelerate PhenoTest BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples.
May 2017—Inova Diagnostics announced that the FDA has granted 510(k) clearance for its Nova Lite DAPI ANCA (ethanol) and Nova Lite DAPI ANCA (formalin) kits for use with Nova View, a digital IFA microscope. Nova Lite DAPI ANCA kits detect anti-neutrophil cytoplasmic antibodies on an automated digital IFA microscope.
May 2017—Randox has launched Acusera 24.7 Live Online 2.0, which is faster than the previous version, has a simplified user interface, and an enhanced user experience. The biggest update to version 2, according to a company statement, is the ability to review peer data in real time, which enhances troubleshooting capabilities and allows labs to identify trends.
May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.
May 2017—EntroGen has launched two sample quality assessment products to determine the quantity and quality of DNA samples prior to running downstream qPCR and NGS experiments. The DNA Fragmentation Quantification Assay and Library Quantification Kit for Illumina save samples, time, and reagents by implementing quality control steps before preparing libraries, loading a flow cell for sequencing, and setting up a qPCR or NGS assay. Both assays rely on real-time PCR technology and require a real-time PCR instrument capable of detecting FAM and VIC.
May 2017—Asuragen entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics. Asuragen will leverage its AmplideX PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument.
May 2017—Nova Biomedical received the CE mark for its Allegro, a capillary blood analyzer for point-of-care testing in primary care settings. Allegro and its StatStrip A companion meter provide 14 clinically important tests to monitor glycemic control, assess cardiac risk with a full lipids panel, and assess kidney function. Results are ready during the patient visit.
